Bausch & Lomb Corp
No SEC Form 4 filings for $BLCO in the last 30 days.
See all $BLCO insider activity →Bausch + Lomb (BLCO) said its experimental glaucoma eye drop BL1107 failed in a mid-stage trial of 159 patients. After 28 days it did not improve visual field scores, though it lowered eye pressure and showed no new safety issues. The company halted daily-drop development and will pursue a sustained-release implant for geographic atrophy instead.
Bausch + Lomb (BLCO) reported Q2 2026 revenue of $1.394B, up 8% constant currency, and adjusted EBITDA of $246M, up 28%, with margin at 17.6%. Surgical, Pharmaceuticals, and Vision Care all grew. Full-year guidance raised to revenue $5.440B-$5.540B and adjusted EBITDA $1.025B-$1.075B. Net leverage fell to 4.7x.
Bausch + Lomb (NYSE/TSX: BLCO) said its board will add four directors effective Aug. 5, 2026 at the request of Bausch Health, which owns about 87% of Bausch + Lomb shares. The company reported Q2 revenue of $1.394B and reaffirmed 2026 guidance: revenue $5.440B to $5.540B and Adjusted EBITDA $1.025B to $1.075B.
Over the past 7 days, alphai's AI scored 5 news stories mentioning BLCO (Bausch & Lomb Corp). Coverage has skewed bullish: 3 bullish, 1 neutral, and 1 bearish.
Recent BLCO coverage spans earnings, technology and corporate actions.
Clinical failure for BL1107 increases near-term uncertainty around the glaucoma pipeline and shifts focus to other ophthalmology programs.
Guidance raise plus margin and cash-flow improvement suggests a near-term positive earnings revision cycle, but pivotal-study miss on enVista Beyond adds regulatory and timeline risk.
Guidance reaffirmation with Q2 cash flow improvement supports the base-case earnings trajectory, while board refresh signals governance alignment with the controlling shareholder.
Board refresh and reaffirmed 2026 guidance are near-term sentiment drivers, but the disclosure is more governance and confirmation than a new operating datapoint.
Guidance raise and earnings beat narrative likely supports near-term upside bias, but profitability concerns are flagged.
alphai scores every news story that mentions BLCO with an AI model for sentiment and relevance, and aggregates insider trades from Bausch & Lomb Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Bausch + Lomb (BLCO) said its experimental glaucoma eye drop BL1107 failed in a mid-stage trial of 159 patients. After 28 days it did not improve visual field scores, though it lowered eye pressure and showed no new safety issues. The company halted daily-drop development and will pursue a sustained-release implant for geographic atrophy instead.
3 min readBausch + Lomb (BLCO) reported Q2 2026 revenue of $1.394B, up 8% constant currency, and adjusted EBITDA of $246M, up 28%, with margin at 17.6%. Surgical, Pharmaceuticals, and Vision Care all grew. Full-year guidance raised to revenue $5.440B-$5.540B and adjusted EBITDA $1.025B-$1.075B. Net leverage fell to 4.7x.
7 min readBausch + Lomb (NYSE/TSX: BLCO) said its board will add four directors effective Aug. 5, 2026 at the request of Bausch Health, which owns about 87% of Bausch + Lomb shares. The company reported Q2 revenue of $1.394B and reaffirmed 2026 guidance: revenue $5.440B to $5.540B and Adjusted EBITDA $1.025B to $1.075B.
4 min readBausch & Lomb Corp (BLCO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-99.1 2 dp251415_ex9901.htm EXHIBIT 99.1 Exhibit 99.1 Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance VAUGHAN, Ontario, Aug. 6, 2026 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to
4 min readBausch + Lomb Corp’s BLCO.TO shares rose 4.14% this week to close at C$23.66, despite a 0.42% dip on the prior day. The move followed its Q2 2026 earnings, which met estimates, and an increase to 2026 revenue guidance, according to the article. Analysts’ average 12-month target is C$25.39 (+7.3%).
3 min readAdjusted gross margin was 62.2%, up 160 basis points year over year, supported by a higher mix of premium products in pharmaceuticals and surgical, as well as productivity efforts. The company invested $114 million in adjusted research and development, an increase of 19% from the prior-year period. Adjusted SG&A margin improved by approximately 130 basis points. Bausch + Lomb raised its 2026 revenue guidance by $20 million to a range of $5.440 billion to $5.540 billion.
4 min readBausch + Lomb (BLCO) shares rose 2.3% in pre-open after it reported Q2 2026 revenue of $1.39B, above the $1.37B consensus, and adjusted EPS of $0.15 matching estimates. The company raised full-year 2026 revenue guidance to $5.44B-$5.54B. Operating income improved to $83M and operating cash flow rose to $153M. UBS initiated Buy coverage.
4 min readBausch + Lomb (NYSE/TSX: BLCO) reported Q2 2026 revenue of $1.394B, up 9% year over year (8% constant currency). GAAP net loss was $14M versus $62M a year earlier. Adjusted EBITDA was $241M. The company raised full-year 2026 revenue and adjusted EBITDA guidance and cited growth in Surgical and Pharmaceuticals.
6 min readBausch & Lomb Corp (BLCO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991q2-2026.htm EX-99.1 Document Exhibit 99.1 Bausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance • Revenue of $1.394 Billion • Revenue Grew 9% as Reported and 8% on a Constant Currency 1 Basis Compared to the Second Quarter of 2025
4 min readBausch + Lomb (NYSE: BLCO) is set to report earnings Wednesday before market open. The company last quarter reported revenue of $1.24 billion, up 9.4% year over year, and beat EPS and revenue expectations, with full-year guidance slightly above analysts’ estimates. For the upcoming quarter, analysts expect revenue growth of 7.2% and an average price target of $18.14 versus $16.25.
3 min read
